ANDA 218866, held by Aurobindo Pharma Ltd. Upadacitinib.
As of Nov 15, 2026, ANDA 218866 (Upadacitinib), held by Aurobindo Pharma Ltd, was first approved by FDA on Oct 16, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 16, 2026 | Original application | Approved |
| Upadacitinib15MG · tablet, extended release;oral | Upadacitinib | Rx |
| Upadacitinib30MG · tablet, extended release;oral | Upadacitinib | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters